SOHO 2018 | Future directions for MLL therapy

Rob Pieters

Rob Pieters, MD, PhD, of Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands, discusses potential target areas of research for mixed lineage leukemia (MLL) rearranged acute lymphoblastic leukemia (ALL) treatments. He explains how oncogenic secondary abnormalities have been observed, specifically in the RAS pathway, thus RAS inhibitors have become a target for therapy and research. Prof Pieters also states that CAR T-cell therapy should be further studied in infants as currently research is minimal. This was recorded at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX.

Share this video